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Abstract
Background: New-generation cell-based assays have demonstrated a robust association of serum autoantibodies
to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis,
and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis
(ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in
MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD).
Objective: To describe systematically the CSF profile in MOG-EM.
Material and methods: Cytological and biochemical findings (including white cell counts and differentiation;
frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios;
intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/
IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody
indices; CSF total protein; CSF L-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian
descent with MOG-EM were analyzed retrospectively.
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Results: Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in
almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in
100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly
restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and
monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found
less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood–CSF barrier dysfunction (as
indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of
all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with
acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels
correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis,
blood–CSF barrier dysfunction was present also during remission in a substantial number of patients.
Conclusion: MOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings
are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the
immunopathogenesis of this newly described autoimmune disease.
Keywords: Myelin oligodendrocyte glycoprotein (MOG), Antibodies, Encephalomyelitis, Cerebrospinal fluid, Lumbar
puncture, Optic neuritis, Transverse myelitis, Neuromyelitis optica (Devic syndrome), Acute disseminated
encephalomyelitis (ADEM), Multiple sclerosis (MS), Oligoclonal bands, MOG antibody-associated disease (MOGAD)
Introduction
Over the past few years, several studies using new-
generation cell-based assays (CBA) have demonstrated a
robust association of immunoglobulin G (IgG) autoanti-
bodies targeting full-length, conformationally intact hu-
man myelin oligodendrocyte glycoprotein (MOG) with
(mostly recurrent) optic neuritis (ON), myelitis, and
brainstem encephalitis, as well as with neuromyelitis
optica (NMO)-like and acute-disseminated encephalo-
myelitis (ADEM)-like presentations, rather than with
classic multiple sclerosis (MS) [1–13]. Based on evidence
from (a) immunological studies suggesting a direct
pathogenic impact of MOG-IgG, (b) neuropathological
studies demonstrating discrete histopathological fea-
tures, (c) serological studies reporting a lack of
aquaporin-4 (AQP4)-IgG in almost all MOG-IgG-
positive patients, and (d) cohort studies suggesting dif-
ferences in clinical and paraclinical presentation, treat-
ment response and prognosis, MOG-IgG is now
considered to denote a disease entity in its own right,
distinct from classic MS and from AQP4-IgG-positive
NMO spectrum disorders (NMOSD) [14–19], which is
now often referred to as MOG-IgG-associated enceph-
alomyelitis (MOG-EM) or MOG-IgG-associated auto-
immune disease [11, 20, 21].
So far, only limited data are available on the cerebro-
spinal fluid (CSF) profile in MOG-EM. Previous studies
were either based on relatively small patient numbers,
included mainly pediatric patients, and/or did not take
into account Caucasian patients. Moreover, all investi-
gated only a small number of selected CSF parameters.
Finally, none of the previous studies required confirm-
ation of MOG-IgG seropositivity by means of a second
assay. This is problematic, given the limited specificity of
some of the currently available assays.
For this study, we systematically and comprehensively
analyzed the results of 163 lumbar punctures (LP) from
a cohort of 100 adult patients of mainly Caucasian des-
cent with MOG-IgG-positive EM.
Patients and methods
Patients
Results from 163 lumbar punctures (LP) in 100 adult
MOG-IgG-positive patients were analyzed retrospectively.
MOG-EM was defined as monophasic or relapsing acute
ON, myelitis, brainstem encephalitis, or encephalitis asso-
ciated with MRI or (in the case of ON only) electrophysio-
logical findings compatible with CNS demyelination and
with MOG-IgG as detected by means of a cell-based assay
(CBA) employing human full-length MOG as antigen
[22]. Longitudinally extensive transverse myelitis (LETM)
was defined as acute myelitis with at least one contiguous
lesion extending over three or more vertebral segments
(VS) as detected by T2-weighted or Gd-enhanced T1-
weighted magnetic resonance imaging (MRI) [31,
32]. Cases of acute myelitis in which no lesion extended
over more than two segments were classified as non-
longitudinally extensive transverse myelitis (NETM). All
patients were diagnosed with MOG-EM at German (Hei-
delberg, Berlin, Munich, Hanover, Düsseldorf, Bochum,
Göttingen, Münster), Austrian (Vienna), and Danish
(Odense) university hospitals. All eligible patients seen at
the respective centers were included [22]. Assays used in-
cluded three live CBA (Medical University Innsbruck,
Austria; University of Vienna, Austria; Ludwig Maximilian
University Munich, Germany) [1, 23–25], an in-house
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fixed CBA (University of Heidelberg, Germany) [2, 26]
and a commercial fixed CBA (Euroimmun, Lübeck,
Germany). Ninety-seven of 100 patients (97%) were tested
by means of two or more independent CBA, including by
at least one live CBA and one fixed CBA. None of the pa-
tients was positive for AQP4-IgG. Results from follow-up
LP (i.e., any LP performed during the course of disease
but after the first LP) were available for 36/100 (36%) pa-
tients. In total, 63 follow-up CSF examinations were per-
formed (median 1 follow-up examination per patient;
range 1-7). The first LP was performed after a median of
10 days after disease onset and the follow-up LP after a
median of 16 days of the last previous attack; the propor-
tion of samples taken during relapse did not significantly
differ between the two groups (84.2% vs. 81.1%). The
mean time interval between LPs was 424 days (median
79 days). The study was approved by the review boards of
the participating centers. Patients gave written informed
consent. LPs were performed for diagnostic purposes in
all cases; no samples were obtained for this study.
Evaluation of the humoral immune response
Oligoclonal IgG bands were assessed by isoelectric focusing
and evaluated according to an international consensus
[27]. Immunoglobulins and albumin were measured
immunonephelometrically. Quantitative expressions of the
intrathecal humoral immune response were based on the
calculation of the CSF/serum quotients QIgG, QIgM, and
QIgA with QIg = IgCSF[mg/l]/Igserum[g/l]. The upper limits of
the respective reference ranges, Qlim(IgG), Qlim(IgM), and
Qlim(IgA), were calculated against QAlb according to Rei-
ber’s revised hyperbolic function [28]. Values for QIg ex-
ceeding Qlim(Ig) were considered to indicate intrathecal
immunoglobulin synthesis [28]. The fraction (in %) of
intrathecally produced Ig (IgIF) and the absolute amount of
locally, i.e., intrathecally, produced Ig (IgGloc) were calcu-
lated according to the following formulas: IgIF[%] = [QIgG
− Qlim(Ig)] × Igserum × 100 and Igloc[mg/L] = [QIg − Qlim(Ig)]
× Igserum, respectively [28]. CSF and serum concentrations
for immunoglobulins and albumin, respectively, were ana-
lyzed within the same analytical series.
Evaluation of the blood–CSF barrier
The CSF/serum albumin quotient, QAlb = AlbCSF[mg/l]/
Albserum[g/l], was used to assess the blood–CSF barrier
(BCB) function. As the upper reference limit of QAlb is
age-dependent, Qlim(Alb) was calculated as 4 + (a/15) ×
10−3 with a representing patient’s age according to Rei-
ber et al. (1994) [29]. Dysfunction of the BCB was de-
fined as QAlb > Qlim(Alb).
Cytological examination, total CSF protein, and L-lactate
A white cell count > 5/μl was classified as increased [30]. An
age-dependent reference range for CSF L-lactate was applied
(16–50: 2.1mmol/l, > 50: 2.6mmol/l) [30]. The upper refer-
ence limit for total CSF protein was set at 0.45mg/l [30].
Statistics
Samples were analyzed in total as well as after stratifica-
tion according to disease status and treatment status.
Fisher’s exact test, the Mann–Whitney U test, and the
Kruskal–Wallis test were used to detect statistical differ-
ences between groups. Spearman’s rho was assessed to
test for correlations. Due to the exploratory nature of
this study, no correction for multiple testing was applied
other than Dunn’s post test. Reiber diagrams (reiber-
grams) were generated using Protein Statistics in CSF
analysis V3.0 software (Comed, Soest, Germany).
Results
Patient characteristics
The median age at LP was 38 years (range 18-78). The
male to female ratio was 1:1.4. A total of 92.6% of all
samples were obtained from patients of Caucasian des-
cent; 7.4% from patients of either Arabian or Asian des-
cent. The median disease duration was ≤ 1 month at the
time of LP (maximum 489months) and 29 months
(range 0-511) at the last follow-up. Information on the
date of onset of the last attack prior to LP was available
from the patient records for 148 samples. Of those, 123
(83.1%) were obtained within 45 days (median 9 days;
range 0-44) after the onset of an acute attack (acute
myelitis with or without other symptoms in 45.5%
[“acute MY subgroup”]; acute ON but no myelitis in
43.1% [“acute ON subgroup”]; neither myelitis nor ON
but isolated brain or brainstem/cerebellar disease in
8.9% [“acute BRAIN subgroup”]; missing data for 3 sam-
ples). Twenty-five samples were obtained more than 90
days after attack onset (“remission subgroup”). Thirty-
five (63.6%) of 55 samples from patients with acute mye-
litis and available MRI data were obtained during epi-
sodes of LETM. The median cumulative spinal cord lesion
load (summing up lesions in patients with multiple lesions)
was 5 VS (up to 21 VS) in the total myelitis group and 6 VS
(range 3-21) in the LETM subgroup. Of the ON samples,
71.7% were taken during attacks of unilateral and 22.6%
during attacks of bilateral ON. Attack severity was classified
by the treating physicians as “mild” or “moderate” in 64.9%
and as “severe” in 27.2% (no data in the remainder). At last
follow-up, 77% of all patients had experienced at least two
attacks (“relapsing subgroup”) and 23% of patients had not
relapsed (“monophasic subgroup”). At first LP, 67/98
(68.4%) patients were neither treated with steroids nor with
immunosuppressants or immunomodulatory drugs at the
time of LP (no precise data on the treatment status at the
time of LP available for 2 patients). If all LPs are considered,
98/163 (60.1%) were obtained from patients who were un-
treated at the time of LP (no precise data for 5 samples).
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Fig. 1 CSF white cell counts, IgG, IgA, IgM, and albumin CSF/serum ratios and CSF concentrations, CSF total protein concentrations, and CSF L-lactate
concentrations in MOG-IgG-positive EM. A statistically significant difference between the acute MY subgroup and the acute ON subgroup was found
with regard to all parameters studied. IgG/A/M, immunoglobulin G/A/M; QIgG/A/M, CSF/serum IgG/A/M ratios; QAlb, CSF/serum albumin ratio
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Cellular immune response
An increased CSF white cell count (WCC) was found
in 82/159 (51.6%) samples examined, with a median
of 31 cells/μl (range, 6-463). WCC ≥ 50 cells/μl,
which are very rare in MS (and thus considered a
'red flag' that should prompt physicians to challenge a
diagnosis of MS) [27, 33], were present in 19.1% (30/
157) of samples. Severe pleocytosis, defined as WCC
≥ 100 cells/μl, was found in 19/157 (12.1%) samples
(median, 177; range, 108-463), 18 of which were
taken during an acute attack (unknown disease activ-
ity in the remaining patient) and 13 of which were
obtained from untreated patients. CSF WCC exceeded
200 cells/μl only in 7/157 (4.5%) samples and 300
cells/μl in 3 samples (1.9%). In total, pleocytosis was
noted at least once in 56/99 (56.6%) patients with
available data.
Lymphocytes, found in 77/77 (100%) samples with
available cytological data, and monocytes, detected in
57/77 (74%) samples, were the predominant immune
cell types in the CSF. Relative lymphocyte counts
ranged between 33% and 100% (median 80%; N = 53)
of all CSF cells and relative monocyte counts between
1% and 75% (median 20%; N = 47).
Importantly, however, neutrophils were present in
at least 42.9% (33/77) of samples. Neutrophils repre-
sented up to 66% of all leukocytes (data available for
29 samples) and up to 41% in samples with pleocyto-
sis (N = 19). If only LPs with pleocytosis and avail-
able cytological data are considered, neutrophil
granulocytes were present even in 50% (22/44) of
samples. Neutrophils were more commonly found
during acute attacks in the MY and BRAIN sub-
groups (57% of all samples with available data) than
in the acute ON subgroup (25%). In total, neutrophil
granulocytes were present at least once in 26/56
(46.4%) patients with available cytology data.
By contrast, eosinophils and basophils were rare
findings, present in only 2/77 (2.6%) and 2/77 (2.6%)
samples, respectively. Activated lymphocytes were
noted in 12/77 (15.6%) samples and plasma cells in 3/
77 (3.9%).
Pleocytosis was significantly less common in the acute
ON subgroup than in the acute MY subgroup (34% vs.
85.2%) (p < 0.000001). Similarly, median cell numbers
were lower in the acute ON subgroup (3, range 0-135,
vs. 45.5 cells/μl, range, 1-463) (p < 0.000001) (Fig. 1);
CSF WCC ≥ 50 cells/μl were found almost exclusively in
patients with acute myelitis at the time of LP (present in
46.3%, or 25/54, vs. 1.9%, or 1/52, in the acute ON sub-
group). See Table 1 and Supplementary Figure 1 for fur-
ther details.
Pleocytosis was also significantly more frequent in
samples obtained during acute attacks (p < 0.005); simi-
larly, cell numbers were significantly higher during acute
attacks (p < 0.0007) (Fig. 2, Table 1, and Supplementary
Figure 1). While activated lymphocytes, eosinophils, and
basophils were noted only during acute attacks, neutro-
phils were found with similar frequency during acute at-
tacks and in remission (44.8% vs. 42.9%).
Table 1 CSF white cell counts (WCC) and cytology results in MOG-IgG-positive EM






CSF white cell counts
Pleocytosis Samples 82/159 (51.6%) 72/120 (60%) 7/25 (28%) 46/54 (85.2%) 18/53 (34%) 6/10 (60%)
WCC, all samples Cells/μl 6 (0-463; 155) 9 (0-463; 118) 2.5 (0-37; 24) 45.5 (1-463; 54) 3 (0-135; 51) 13.5 (0-68; 10)
WCC, if elevated Cells/μl 31 (6-463; 80) 40 (6-463; 71) 21 (13-37; 7) 60.15 (6-463; 46) 9 (6-135; 17) 16.5 (12-68; 6)
WCC, > = 100 Samples 19/157 (12.1%) 18/119 (15.1%) 0/25 (0%) 17/54 (31.5%) 1/52 (1.9%) 0/10 (0%)
WCC, > = 100 Cells/μl 177 (108-463; 19) 181.5 (108-463; 18) n.a. (n.a.; 0) 186 (108-463; 17) 135 (135-135; 1) n.a. (n.a.; 0)
Lymphocytes Samples 77/77 (100%) 58/58 (100%) 14/14 (100%) 30/30 (100%) 24/24 (100%) 4/4 (100%)
Monocytes Samples 57/77 (74%) 42/58 (72.4%) 11/14 (78.6%) 20/30 (66.7%) 18/24 (75%) 4/4 (100%)
Neutrophils Samples 33/77 (42.9%) 26/58 (44.8%) 6/14 (42.9%) 17/30 (56.7%) 6/24 (25%) 3/4 (75%)
Eosinophils Samples 2/77 (2.6%) 2/58 (3.4%) 0/14 (0%) 1/30 (3.3%) 0/24 (0%) 1/4 (25%)
Basophils Samples 2/77 (2.6%) 2/58 (3.4%) 0/14 (0%) 2/30 (6.7%) 0/24 (0%) 0/4 (0%)
Plasma cells Samples 3/77 (3.9%) 2/58 (3.4%) 1/14 (7.1%) 2/30 (6.7%) 0/24 (0%) 0/4 (0%)
Lymphoid cells Samples 12/77 (15.6%) 10/58 (17.2%) 0/14 (0%) 6/30 (20%) 4/24 (16.7%) 0/4 (0%)
Macrophages Samples 6/77 (7.8%) 3/58 (5.2%) 2/14 (14.3%) 0/30 (0%) 2/24 (8.3%) 1/4 (25%)
No pleocytosis Samples 77/159 (48.4%) 48/120 (40%) 18/25 (72%) 8/54 (14.8%) 35/53 (66%) 4/10 (40%)
WCC in the various subgroups are reported as medians; ranges and total sample numbers are given in brackets
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After exclusion of three outliers with excessive WCC
(≥ 300/μl), a significant negative correlation of CSF
WCC with days since attack onset was noted in patients
with acute myelitis (r = − 0.347, p < 0.02) (Fig. 3). No
significant correlation between WCC and the cumulative
spinal cord lesion load during acute myelitis attacks
could be found in the total cohort, but WCC were corre-
lated with spinal cord lesion load after exclusion of out-
liers with unusually high lesion load (≥ 15 VS) (r=0.461,
p < 0.004) (Fig. 4).
Intrathecal IgG synthesis
CSF-restricted OCB were positive in only 20/151 (13.2%)
samples (OCB pattern 2 in 14/150 or 9.3%; pattern 3 in
5/150 or 3.3%; no data in 1), and QIgG was elevated in
just 11/133 (8%) (median QIgG 4; range 2.3-7) (Table 2).
In 28/150 (18.7%) samples, identical OCB in serum and
CSF but no CSF-restricted bands were present (pattern
4). Pattern 5, indicating monoclonal gammopathy, was
present in 2/150 samples (1.3%) from two patients.
Overall, 15/100 (15%) patients showed CSF-restricted
Fig. 2 CSF white cell counts, IgG, IgA, IgM, and albumin CSF/serum ratios and CSF concentrations, CSF total protein concentrations, and CSF L-
lactate concentrations during acute attacks and remission in MOG-IgG-positive EM. IgG/A/M, immunoglobulin G/A/M; MY, myelitis; QIgG/A/M,
CSF/serum IgG/A/M ratios; QAlb, CSF/serum albumin ratio
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OCB at least once, and QIgG was positive in 9/88
(10.2%) patients at least once.
Not only the frequency but also the degree of intrathecal
synthesis (IS) was low: QIgG was elevated in only 41.2% of
the OCB-positive samples. In those samples with elevated
QIgG, the intrathecal IgG fraction exceeded the first decile
(values < 10% may result from the imprecision of nephelo-
metric IgG testing and should thus not be taken as
strict proof of IS according to current guidelines [30]) in only
19% of cases, the median IF-IgG was just 10.5% (range 1.13-
53.3%), and the median absolute amount of intrathecally pro-
duced IgG was just 2.3 mg/l (range 0.29 to 25 mg/l).
Fig. 3 Correlation analyses for CSF white cell counts (after exclusion of three outliers >300 cells/μl), QAlb and CSF total protein, respectively, with
time since attack onset in patients with acute MOG-IgG-positive myelitis
Fig. 4 Correlation of CSF L-lactate concentrations, QAlb, QIgG, and CSF WCC with the spinal cord lesion load (as measured in vertebral segments)
in patients with acute MOG-IgG-positive myelitis. Note that the CSF WCC correlated with the spinal lesion load only after exclusion of outliers
with extraordinarily high lesion load (15 or more segments). The most significant correlation was found with CSF L-lactate levels. QAlb, albumin
CSF/serum ratio, QIgG, IgG CSF/serum ratio; WCC, white cell count
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While OCB were detectable with similar frequency both
during acute attacks (13/112; 11.6%) and in remission (2/
24; 8.3%), larger amounts of intrathecally produced IgG as
indicated by an IgG-IF > 10% were found exclusively in
samples obtained during acute attacks (Table 2). To evalu-
ate whether the frequency of OCB increases with disease
duration, we compared samples obtained within the first
month since disease onset and samples obtained more
than 1 year after disease onset but found no statistically
significant difference regarding the rate of OCB positive
samples (15.9% or 10/63, vs. 6.7% or 3/45); if only samples
taken during acute attacks are considered, no sample ob-
tained > 1 year after disease onset was positive for OCB
(15.9% or 10/63, vs. 0% or 0/27; p < 0.03).
CSF IgG concentrations exceeded the reference range
of 40 mg/l in 37/111 (33.3%) OCB-negative samples.
However, in none of these cases QIgG was elevated.
This indicates that the high CSF IgG concentrations in
these samples were caused by passive transfer of IgG ra-
ther than by intrathecal synthesis. In fact, QAlb was in-
creased in 94% (34/36) of these patients, indicating
blood CSF barrier dysfunction.
There was a trend towards a higher frequency of CSF-
restricted OCB (pattern 2 or 3) in the acute MY subgroup
than in the acute ON subgroup (14% vs. 6%; p = n.s.) (Table
2). Similarly, QIgG was slightly more frequently elevated
(12.8% vs. 4.5%; p = n.s.) and median IgG CSF/serum ratios
(4.2 vs. 2.66; p < 0.0002) as well as CSF IgG levels (39.8 vs.
28.9 mg/dl; p < 0.02) were significantly higher in the acute
MY subgroup (Table 2 and Fig. 1). In patients with acute
myelitis, QIgG also correlated with the spinal cord lesion
load (as measured in VS) (r = 0.391, p < 0.01) (Fig. 4).
Table 2 Frequency of intrathecal IgG synthesis, oligoclonal IgG pattern, IgG CSF/serum ratios, intrathecal IgG fractions, absolute
amount of locally produced IgG, and absolute IgG concentrations in the CSF and serum









Samples 20/151 (13.2%) 13/112 (11.6%) 2/24 (8.3%) 7/50 (14%) 3/51 (5.9%) 2/10 (20%)
OCB positive Samples 20/151 (13.2%) 13/112 (11.6%) 2/24 (8.3%) 7/50 (14%) 3/50 (6%) 2/10 (20%)
OCB pattern 1 Samples 101/150 (67.3%) 77/112 (68.8%) 18/24 (75%) 30/50 (60%) 41/50 (82%) 5/10 (50%)
OCB pattern 2 Samples 14/150 (9.3%) 9/112 (8%) 2/24 (8.3%) 3/50 (6%) 3/50 (6%) 2/10 (20%)
OCB pattern 3 Samples 5/150 (3.3%) 4/112 (3.6%) 0/24 (0%) 4/50 (8%) 0/50 (0%) 0/10 (0%)
OCB pattern 4 Samples 28/150 (18.7%) 20/112 (17.9%) 4/24 (16.7%) 11/50 (22%) 6/50 (12%) 3/10 (30%)
OCB pattern 5 Samples 2/150 (1.3%) 2/112 (1.8%) 0/24 (0%) 2/50 (4%) 0/50 (0%) 0/10 (0%)
OCB pattern 2 or 3 Samples 19/150 (12.7%) 13/112 (11.6%) 2/24 (8.3%) 7/50 (14%) 3/50 (6%) 2/10 (20%)
OCB pattern 3 or 4 Samples 33/150 (22%) 24/112 (21.4%) 4/24 (16.7%) 15/50 (30%) 6/50 (12%) 3/10 (30%)
OCB pattern 1, 4, or 5 Samples 131/150 (87.3%) 99/112 (88.4%) 22/24 (91.7%) 13/50 (86%) 6/50 (94%) 3/10 (80%)
QIgG > Qlim(IgG) Samples 11/133 (8%) 9/100 (9%) 1/23 (4%) 6/47 (12.8%) 2/44 (4.5%) 1/8 (12.5%)
QIgG, all LPs - 3.5 (0.9-23.6; 131) 3.5 (0.9-23.6; 99) 3.2 (1.5-14.7; 23) 4.2 (1.11-23.61; 47) 2.66 (1.32-14.09; 43) 4.24 (0.9-4.96; 8)
QIgG, if positive - 4 (2.3-7; 10) 4.5 (2.37; 9) 3.2 (3.2-3.2; 1) 5.92 (2.26-7.01; 6) 4.02 (3.57-4.47; 2) 2.37 (2.37-2.37; 1)
IgG IF, all LPs % IgG(CSF) 0 (0-53.3; 131) 0 (0-53.3; 99) 0 (0-6.8; 23) 0 (0-53.3; 47) 0 (0-26.4; 43) 0 (0-1.1; 8)
IgG IF, QIgG positives % IgG(CSF) 10.5 (1.13-53.3; 10) 14.2 (1.1-53.3; 9) 6.8 (6.8-6.8; 1) 11.9 (4.5-53.3; 6) 20.3 (14.2-26.4; 2) 1.1 (1.1-1.1; 1)
IgG IF, > 10% Samples 5/131 (3.8%) 5/99 (5.1%) 0/23 (0%) 3/47 (6.4%) 2/43 (4.7%) 0/8 (0%)
IgG Loc, all LPs mg/l 0 (0-25; 127) 0 (0-25; 96) 0 (0-2.1; 22) 0 (0-25; 45) 0 (0-0.3; 8) 0 (0-25; 96)
IgG Loc, QIgG
positives
mg/l 2.3 (0.29-25; 9) 4.7 (0.3-25; 8) 2.1 (2.1-2.1; 1) 2.3 (1.1-25; 5) 9.7 (7.9-11.6; 2) 0.3 (0.3-0.3; 1)
IgG CSF, all LPs mg/l 33.1 (11-236.1; 129) 33.3 (11-236.1; 96) 32.4 (13-182; 22) 39.8 (11-236.1; 45) 28.9 (14.6-121; 42) 27 (17-58; 8)
IgG CSF, QIgG
positives
mg/l 38 (22.5-75.7; 9) 41 (22.5-75.7; 8) 30.9 (30.9-30.9; 1) 38 (22.5-75.7; 5) 49.7 (44-55.4; 2) 25.8 (25.8-25.8; 1)
IgG serum, all LPs g/l 9.9 (4-31.8; 127) 9.9 (4-31.8; 96) 9.8 (6-12.4; 22) 9.4 (4-31.8; 45) 10.2 (5.86-23.9; 42) 10.84 (4-31; 8)
IgG serum, QIgG
positives
g/l 10 (6.3-15.5; 9) 10.4 (6.3-15.5; 8) 9.6 (9.6-9.6; 1) 10 (6.3-11.1; 5) 12.7 (9.8-15.5; 2) 10.9 (10.9-10.9; 1)
Link index, all Samples 13/131 (10%) 9/99 (9%) 4/23 (17%) 7/47 (14.9%) 2/43 (4.7%) 0/8 (0%)
Link index, if positive Index 0.8 (0.7-1.7; 13) 0.8 (0.7-1.5; 9) 1.2 (0.7-1.7; 4) 0.8 (0.7-1.5; 7) 0.9 (0.8-0.9; 2) n.a. (n.a.; 0)
Quotients, indices, concentrations, and fractions are given as median and range
QIgG/A/M CSF/serum IgG/A/M ratio, IgG/A/M IF intrathecally produced IgG/IgA/IgM fraction, IgG/A/M loc locally (intrathecally) produced IgG/A/M, LP
lumbar puncture
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IgG serum levels were elevated in 4/127 (3.1%) sam-
ples, all of which were taken during acute attacks. Me-
dian IgG serum concentrations did not differ
significantly between acute samples and samples ob-
tained during remission (Table 2) and also not between
the acute MY and the acute ON subgroup (Supplemen-
tary Figure 2).
Intrathecal IgM synthesis
QIgM was increased in 13/112 (12%) samples (median
1.9; range, 0.6-9.6) from 10 patients. In those samples with
elevated QIgM, the fraction of intrathecally produced IgM
varied between 1 and 59.1% (median 9.2%), corresponding
to a median absolute amount of intrathecally produced
IgM of 0.32 mg/l (range 0.01-2.3), and was > 10% only in
6 out of those 13 samples. As with IgG, an intrathecal
IgM fraction of > 10% was observed only during acute at-
tacks. Also QIgM was exclusively elevated during acute
attacks (Table 3). More samples in the acute MY sub-
group than in the acute ON subgroup showed IgM IS
(24% vs. 8%), but the difference was not statistically signifi-
cant. Median QIgM and the median CSF IgM concentra-
tion were significantly higher in the MY subgroup than in
the ON subgroup (p < 0.000007 and p < 0.008, respect-
ively) (Fig. 1).
Median IgM serum concentrations did not differ sig-
nificantly between acute samples and samples obtained
during remission (Table 3).
Intrathecal IgA synthesis
QIgA was increased in just 5/111 (5%) samples (median
QIgG 2.6; range 1.7-6.2) from 5 patients, with no differ-
ence between patients with acute ON and those with
acute myelitis at the time of LP (5.3% vs. 5.3%) (Table 3
and Fig. 1). Among patients with elevated QIgA, the
fraction of intrathecally produced IgA varied between
3.8 and 34.2% (median, 13.3), corresponding to an abso-
lute amount of intrathecally produced IgA between 0.2
and 2.9 mg/l (median, 0.5). Median IgA CSF concentra-
tions and IgA CSF/serum ratios were significantly higher
Table 3 Frequency of intrathecal IgM and IgA synthesis, IgM and IgA CSF/serum ratios, intrathecal IgM and IgA fractions, amount of
locally produced IgM and IgA, and absolute IgM and IgA concentrations in the CSF and serum







QIgM > Qlim(IgM) Samples 13/112 (12%) 13/84 (15%) 0/20 (0%) 9/38 (24%) 3/39 (8%) 1/6 (17%)
QIgM, all LPs - 0.5 (0-13.8; 111) 0.6 (0-13.8; 83) 0.5 (0-4.1; 20) 1.11 (0-13.81; 38) 0.41 (0-1.82; 38) 0.28 (0-1.9; 6)
QIgM, if positive - 1.9 (0.6-9.6; 13) 1.9 (0.6-9.6; 13) n.a. 2.72 (0.63-9.63; 9) 0.84 (0.68-1.33; 3) 1.9 (1.9-1.9; 1)
IgM IF, all LPs % IgM (CSF) 0 (0-59.1; 111) 0 (0-59.1; 83) 0 (0-0; 20) 0 (0-59.1; 38) 0 (0-41.9; 38) 0 (0-18.3; 6)
IgM IF, QIgM
positives
% IgM (CSF) 9.2 (1-59.1; 13) 9.2 (1-59.1; 13) n.a. (n.a.;0) 9.2 (3.5-59.1; 9) 9 (1-41.9; 3) 18.3 (18.3-18.3; 1)
IgM IF, > 10% Samples 6/111 (5.4%) 6/83 (7.2%) 0/20 (0%) 4/38 (10.5%) 1/38 (2.6%) 1/6 (16.7%)
IgM Loc, all LPs mg/l 0 (0-2.3; 108) 0 (0-2.3; 81) 0 (0-0; 19) 0 (0-2.3; 36) 0 (0-0.3; 38) 0 (0-0.6;6)
IgM Loc, QIgM
positives
mg/l 0.32 (0.01-2.3; 13) 0.32 (0.01-2.3; 13) n.a. 0.3 (0.1-2.3; 9) 0 (0-0.3; 3) 0.6 (0.6-0.6; 1)
IgM CSF mg/l 0.5 (0-16.3; 110) 0.5 (0-16.3; 82) 0.49 (0-3.6; 19) 1.69 (0-16.3; 36) 0.36 (0-1.51; 39) 0.25 (0-4.19; 6)
IgM serum g/l 1.02 (0.15-3.73; 112) 1.03 (0.15-3.73; 84) 0.89 (0.39-2.19; 20) 1.18 (0.3-2.96; 37) 0.94 (0.15-2.41; 40) 1 (0.79-3.73; 6)
Intrathecal IgA synthesis
QIgA > Qlim(IgA) Samples 5/111 (5%) 4/83 (5%) 1/20 (5%) 2/38 (5.3%) 2/38 (5.3%) 0/6 (0%)
QIgA, all LPs - 2 (0-17.3; 110) 1.9 (0-17.3; 82) 2.5 (0-11.1; 20) 2.65 (0-17.27; 38) 1.51 (0-3.22; 37) 2.15 (0-3.26; 6)
QIgA, if positive - 2.6 (1.7-6.2; 5) 2.4 (1.7-6.2; 4) 2.9 (2.9-2.9; 1) 4.42 (2.61-6.24; 2) 1.96 (1.68_2.24; 2) n.a. (n.a.; 0)
IgA IF, all LPs % IgA (CSF) 0 (0-34.2; 110) 0 (0-31.7; 82) 0 (0-34.2; 20) 0 (0-31.7; 38) 0 (0-13.3; 37) 0 (0-0; 6)
IgA IF, QIgA positives % IgA (CSF) 13.3 (3.8-34.2; 5) 9.5 (3.8-31.7; 4) 34.2 (34.2-34.2; 1) 17.8 (3.8-31.7; 2) 9.5 (5.7-13.3; 2) n.a. (n.a.; 0)
IgA IF, > 10% Samples 3/110 (2.7%) 2/82 (2.4%) 1/20 (5%) 1/38 (2.6%) 1/37 (2.7%) 0/6 (0%)
IgA Loc, all LPs mg/l 0 (0-2.9; 106) 0 (0-2.9; 79) 0 (0-2; 19) 0 (0-2.9;36) 0 (0-0.5; 36) 0 (0-0; 6)
IgA Loc, QIgA
positives
mg/l 0.5 (0.2-2.9; 5) 0.5 (0.2-2.9; 4) 2 (2-2; 1) 1.6 (0.4-2.9; 2) 0.4 (0.2-0.5; 2) n.a. (n.a.; 0)
IgA CSF mg/l 3.6 (0-40.7; 109) 3.57 (0-40.7; 81) 4.4 (0-29.1; 19) 4.34 (0-40.7; 36) 3.1 (0-7.99; 38) 3.4 (0-10.4; 6)
IgA serum g/l 1.95 (0.25-7; 108) 1.8 (0.62-7; 81) 2.3 (1.1-3; 19) 1.77 (0.62-7; 37) 2.04 (0.73-5.16; 37) 1.94 (0.67-3.99; 6)
Quotients, concentrations, and fractions are given as median and range
QIgG/A/M CSF/serum IgG/A/M ratio; IgG/A/M IF intrathecally produced IgG/IgA/IgM fraction; IgG/A/M loc locally (intrathecally) produced IgG/A/M; LP
lumbar puncture
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(p < 0.00008 and p < 0.008, respectively) in the acute
MY subgroup than in the acute ON subgroup (Table 3
and Fig. 1).
Median IgA concentrations in the serum did not differ
significantly between acute samples and samples ob-
tained during remission (Table 3 and Fig. 2).
Immunoglobulin (Ig) class patterns
Only 1 out of 107 (0.9%) samples and 1 out of 75 (1.3%)
patients tested exhibited a so-called three-class immune
response as defined by elevation of QIgG, QIgM, and
QIgA (no data in the remainder). While this particular
sample was positive for a three-class reaction also
Table 4 Immunoglobulin class response patterns in MOG-IgG-positive EM
Units Total Attack Remission Acute MY subgroup Acute ON subgroup Acute BRAIN subgroup
a. Based on QIg > Qlim(Ig)
3-class reaction Samples 1/107 (0.9%) 1/81 (1.2%) 0/19 (0%) 1/38 (2.6%) 0/36 (0%) 0/6 (0%)
2-class reaction Samples 5/107 (4.7%) 4/81 (4.9%) 1/19 (5.3%) 2/38 (5.3%) 2/36 (5.6%) 0/6 (0%)
IgG + IgM Samples 3/107 (2.8%) 3/81 (3.7%) 0/19 (0%)
IgG + IgA Samples 2/107 (1.9%) 1/81 (1.2%) 1/19 (5.3%)
IgM + IgA Samples 0/107 (0%) 0/81 (0%) 0/19 (0%)
1-class reaction Samples 15/107 (14%) 15/81 (18.5%) 0/19 (0%) 10/38 (26.3%) 3/36 (8.3%) 2/6 (33.3%)
Only IgG Samples 4/107 (3.7%) 4/81 (4.9%) 0/19 (0%)
Only IgM Samples 9/107 (8.4%) 9/81 (11.1%) 0/19 (0%)
Only IgA Samples 2/107 (1.9%) 2/81 (2.5%) 0/19 (0%)
b. Based on Ig-IF > 10%
3-class reaction# Samples 1/107 (0.9%) 1/81 (1.2%) 0/19 (0%) 1/38 (2.6%) 0/36 (0%) 0/6 (0%)
2-class reaction§ Samples 1/107 (0.9%) 1/81 (1.2%) 0/19 (0%) 1/38 (2.6%) 0/36 (0%) 0/6 (0%)
IgG + IgM Samples 1/107 (0.9%) 1/81 (1.2%) 0/19 (0%)
IgG + IgA Samples 0/107 (0%) 0/81 (0%) 0/19 (0%)
IgM + IgA Samples 0/107 (0%) 0/81 (0%) 0/19 (0%)
1-class reaction Samples 9/107 (8.4%) 8/81 (9.9%) 1/19 (5.3%) 3/38 (7.9%) 4/36 (11.1%) 1/6 (16.7%)
Only IgG Samples 3/107 (2.8%) 3/81 (3.7%) 0/19 (0%)
Only IgM Samples 4/107 (3.7%) 4/81 (4.9%) 0/19 (0%)
Only IgA Samples 2/107 (1.9%) 1/81 (1.2%) 1/19 (5.3%)
#IF in the single sample with a three-class reaction: IgG-IF 18.79%, IgM-IF 21.65% and IgA-IF 31%
§IF in the single sample with a two-class reaction: IgG-IF 33.09% and IgM-IF 59%
Table 5 Antibody indices
Units Total cohort
MRZ reaction (M + R, M + Z, R + Z, or M + R + Z) Patients 0/48 (0%)
MRZ reaction (M + R, M + Z, R + Z, or M + R + Z) Samples 0/62 (0%)
AI measle virus (M) Samples 2/61 (3.3%)
AI rubella virus (R) Samples 1/52 (1.9%)
AI varizella zoster virus (Z) Samples 3/76 (3.9%)
Other antibody indices
AI HSV Samples 3/56 (5.4%)
AI EBV Samples 1/18 (5.6%)
AI CMV Samples 0/26 (0%)
AI B. burgdorferi, IgG Samples 1/77 (1.3%)
AI B. burgdorferi, IgM Samples 0/74 (0%)
MRZ reaction and antibody indices for measles virus (M), rubella virus (R), varicella zoster virus (V), herpes simplex virus (HSV), Epstein Barr virus (EBV),
cytomegalovirus (CMV), and Borrelia burgdorferi (BB)
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according to a stricter definition based on Ig-IF > 10%, it
was negative for OCB, strongly suggesting that the CSF/
serum Ig ratios were falsely positive in this case (prob-
ably owing to plasma exchange [PEX] prior to LP; date
of PEX commencement not precisely documented).
A two-class reaction defined by either positive QIgG
and QIgM, positive QIgM and QIgA, or positive QIgG
and QIgA was detected in only 5/107 (4.7%) samples
and 4/75 (5.3%) patients tested based on QIg > Qlim(Ig)
(Table 4). In 2 of these 5 patients (i.e., in just 2 out of
107 [1.9%] samples) a dominant IgG two-class reaction
was noted; in 2 a dominant IgM reaction; and in 1 a
dominant IgA response. If the stricter definition based
on Ig-IF > 10% is used, the number of samples with a
positive two-class reaction drops to 1/107 (0.9%) (IgM-
dominant) (Table 4). By contrast, an IgG-dominant two-
class response has been reported to occur in 20-40% of
cases in MS [34, 35].
Intrathecal Ig synthesis was restricted to one immuno-
globulin class in 15/107 (14%) samples (IgG in 4; IgM in 9;
IgA in 2) from 12 patients based on Ig CSF/serum ratios
and in 9/107 (8.4%) samples based on Ig-IF > 10% (Table 4).
In two patients with intrathecal IgM and/or IgA syn-
thesis but no quantitative evidence of intrathecal IgG
synthesis, qualitative evidence for intrathecal IgG synthe-
sis, i.e., CSF-restricted OCB, were detectable.
MRZ reaction
Results of measles virus (M), rubella virus (R), and
varicella-zoster virus (Z) antibody index (AI) deter-
mination were available for 61, 52, and 76 samples, re-
spectively. All three AI were tested in 46 samples and
two AI in 16 further samples. A positive MRZR, as de-
fined by the presence of a positive IgG AI for at least
two of its three constituents M, R and Z (i.e., by any of
the following combinations: MR, MZ, RZ, or MRZ), is
detectable in around 63% of cases in MS [36]. By con-
trast, the MRZ reaction was absent in 62/62 (100%)
samples from 48 MOG-IgG-positive patients with
available data (p < 0.000001 when compared to data
from a reference paper on MRZR in MS [37]) (Table 5
and Fig. 5).
Intrathecal production of antibodies to measles (with or
without concomitant antibodies against rubella and zoster
virus) is the most common intrathecal antiviral immune re-
sponse in MS, both in adults and in children [37]. While it is
present in up to 86% of patients with MS, it was present in
only 2/61 (3.3%) MOG-IgG samples (p < 0.000001 when
compared to data from [37]; N = 177). A positive rubella virus
AI was found for only 1/52 (1.9%) samples (p < 0.000001 vs.
MS [37]), and a positive varicella-zoster virus AI for 3/76
(3.9%) (p < 0.000001 vs. MS [37]). However, no patient was
positive for more than one of these AI.
Fig. 5 MRZ reaction. a The antibody indices for M, R, and Z in multiple sclerosis (pooled data from ref. [36, 38]) and in samples from MOG-IgG-
positive patients (present study). Groups were compared using the Kruskal–Wallis test with Dunn’s post test. b The frequency of a positive MRZ
reaction (MR, MZ, RZ, or MRZ) in MOG-EM (present study), in neuromyelitis optica spectrum disorders (NMOSD), and in healthy controls (HC) (data
from [36]). AI, antibody index; M, measles virus AI; R, rubella virus AI; Z, varicella-zoster virus AI
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Median AI for M, R, and Z were significantly lower in
patients with MOG-EM than those in two previously pub-
lished cohorts of patients with MS (p < 0.00001) (Fig. 5).
The MRZ reaction was negative not only in OCB-
negative samples but also in 7/7 (100%) OCB-positive
samples (from 6 different patients).
Other antibody indices
A positive IgG AI (AI = 3.2) for Borrelia burgdorferi was
present only in 1/77 (1.3%) samples from 65 patients
tested. The Borrelia IgM AI was negative in 74 samples
from 62 patients tested, including the Borrelia IgG AI-
positive sample. None of the 26 samples tested exhibited
a positive cytomegalovirus (CMV) IgG AI. A positive
IgG AI for Epstein–Barr virus was noted in a single sam-
ple, while 17 other samples tested were negative. A posi-
tive IgG AI for herpes simplex virus (HSV) was found with
3/56 (5.4%) samples from 3 patients. In none of the Borre-
lia−, EBV−, or HSV-AI-positive patients, other AIs were re-
ported to be elevated (although not all AIs were tested in
all patients). See also Table 5.
Blood–CSF barrier integrity
An elevated CSF/serum ratio for albumin, indicating dys-
function of the BCB, was found with 67/139 (48.2%) sam-
ples and was present at least once in 48/88 (54.5%)
patients tested for this marker. QAlb ranged between 5.5-
32.67 (median 9.6) (Table 6). Although absolute QAlb
values decreased over time after an attack both in the total
cohort (r2 = 0.055, p < 0.02) and in the acute myelitis sub-
group (r2 = 0.126, p < 0.02) (Fig. 3), BCB dysfunction
remained present during remission at almost the same fre-
quency as during acute attacks (43.5% vs 46.7%; Table 6).
In 23 samples (from 19 different patients) of 67 tested
(34.3%), an albumin–cellular dissociation (ACD), i.e.,
compromised integrity of the BCB in the absence of CSF
pleocytosis, was found. ACD was more commonly seen
during remission (p = n.s.), reflecting the fact that pleo-
cytosis was present more often during the acute phase
and that BCB disruption was present also during remis-
sion in many cases (Table 6).
The frequency of BCB dysfunction was higher during
acute MY attacks (56% [28/50]) than during acute ON
attacks (34.8% [16/46]) (p < 0.05) (Table 6). In patients
with acute myelitis, QAlb was positively linked to the
spinal cord lesion load as detected by MRI and mea-
sured in VS (r = 0.386, p < 0.02) (Fig. 4).
Total CSF protein
Total protein (TP) concentrations in the CSF were ele-
vated in 64/146 (43.8%) samples (median 64.65 mg/dl;
range 45.3-176) and at least once in 46/95 (48.4%) patients
with available data. As expected, were significantly related
to QAlb as detected by regression analysis (r2=0.874, p&lt;
Table 6 Blood CSF barrier function, CSF total protein and CSF L-lactate in MOG-IgG-positive EM







QAlb > QAlb(lim) Samples 67/139 (48.2%) 49/105 (46.7%) 10/23 (43.5%) 28/50 (56%) 16/46 (34.8%) 4/8 (50%)
QAlb, all LPs - 6.6 (3-32.7; 138) 6.4 (3-32.7; 105) 6 (3.1-18.5; 23) 7.4 (3.1-32.7; 50) 5.4 (3-26.3; 46) 7.8 (3.6-8.9; 8)
QAlb, if positive - 9.6 (5.5-32.67; 66) 9.2 (5.5-32.67; 49) 11.8 (8.08-18.51; 10) 10.8 (6.4-32.7; 28) 7.8 (5.5-26.3; 16) 8 (6.8-8.9; 4)
Alb CSF mg/l 273 (123-1260; 131) 261.5 (123-1260; 98) 280 (123-694; 22) 305 (133-1038.9; 46) 218 (123-1260; 43) 310 (175-371; 8)
Alb serum g/l 42.1 (25.9-50.6; 126) 42.15 (25.9-50.6; 94) 41.8 (33.5-49.8; 22) 42.2 (25.9-50.6; 46) 42.2 (32.4-50.4; 39) 41.9 (37.3-48.7; 8)
Albumin-cellular dissociation Samples 23/67 (34.3%) 14/49 (28.6%) 4/10 (40%) 2/28 (7.1%) 11/16 (68.8%) 1/4 (25%)
Combined BCB disruption
and intrathecal IgG synthesis Samples 12/67 (17.9%) 8/49 (16.3%) 1/10 (10%) 6/28 (21.4%) 1/16 (6.3%) 1/4 (25%)
CSF total protein
CSF TP, elevated Samples 64/146 (43.8%) 49/110 (44.5%) 9/25 (36%) 27/51 (52.9%) 16/50 (32%) 6/8 (75%)
CSF TP, all LPs mg/dl 43.75 (5.11-176; 136) 43.75 (20.4-176; 102) 40 (5.11-148; 23) 49.6 (20.5-176; 48) 37.2 (20.4-171.8; 46) 48.2 (30.4-74.2; 8)
CSF TP, if elevated mg/dl 64.65 (45.3-176; 64) 65 (45.3-176; 49) 61.9 (47-148; 9) 73.3 (46.7-176; 27) 60.4 (45.3-171.8; 16) 50.7 (47-74.2; 6)
CSF TP, > 100 mg/dl Samples 11/136 (8.1%) 8/102 (7.8%) 2/23 (8.7%) 7/48 (14.6%) 1/46 (2.2%) 0/0 (0%)
CSF L-lactate
CSF L-lactate, elevated Samples 28/107 (26.2%) 25/79 (31.6%) 1/20 (5%) 18/37 (48.6%) 7/39 (17.9%) 0/3 (0%)
CSF L-lactate, all LPs mmol/l 1.8 (1.05-4.43; 103) 1.9 (1.05-4.43; 76) 1.7 (1.33-2.4; 19) 2.31 (1.12-4.43; 35) 1.75 (1.05-2.68; 38) 1.51 (1.5-1.7; 3)
CSF L-lactate, if elevated mmol/l 2.68 (2.1-4.43; 28) 2.68 (2.1-4.43; 25) 2.4 (2.4-2.4; 1) 2.53 (1.88-4.43; 20) 1.7 (1.05-2.68; 10) 1.51 (1.5-1.51; 2)
CSF L-lactate, >3 mmol/l Samples 10/103 (9.7%) 8/76 (10.5%) 0/19 (0%) 8/35 (22.9%) 0/38 (0%) 0/3 (0%)
Ratios and concentrations are given as median (with ranges and sample numbers in brackets)
Alb albumin; BCB blood–CSF barrier; LP lumbar puncture; QAlb CSF/serum albumin ratio; TP total protein
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0.00001) (Supplementary Figure 3). Accordingly, QAlb
was elevated in 85.2% of samples with increased CSF TP
levels and available data on both parameters. Elevated CSF
TP levels were > 45 and < 50mg/dl (“borderline”) in 14/64
(21.9%) samples, ≥ 50 and ≤ 100mg/dl in 39/64 (60.9%), be-
tween > 100 and ≤ 150mg/dl in 9/64 (14.1%), and exceeded
150mg in 2/64 (3.1%). Like QAlb, CSF TP levels were nega-
tively correlated with the time (in days) since the onset of
the last attack both in the total cohort (r2 = 0.061, p < 0.02)
and in the acute myelitis subgroup (r2 = 0.117, p < 0.02)
(Fig. 3). However, CSF TP levels were elevated not only dur-
ing acute attacks (49/110 or 44.5%) but rather frequently
also during remission (9/25 or 36%) (Table 6), which is in
line with the fact that QAlb remained elevated during remis-
sion in many cases as well. Like QAlb, CSF TP levels were
more commonly elevated in the acute MY subgroup than in
the acute ON subgroup and was negatively correlated with
time since attack onset (r2 = 0.117, p < 0.02) (Table 6); also,
median CSF TP levels were higher in the MY subgroup than
in the acute ON subgroup (p < 0.009) (Fig. 1).
Fig. 6 Correlation of CSF L-lactate concentrations with CSF WCC in the total cohort (upper left panel), with CSF WCC in patients with pleocytosis
(upper right panel), QAlb (lower left panel) and QIgG (lower right panel). QAlb, albumin CSF/serum ratio, QIgG, IgG CSF/serum ratio; WCC, white
cell count
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CSF L-lactate
Lactate levels were increased in 28/107 (26.2%) CSF
samples (and at least once in 21/71 [29.6%] patients
tested), with a median concentration of 2.68 mmol/l
(range 2.1-4.43). Elevated lactate levels were found more
frequently during acute attacks than during remission
(31.6% vs. 5%; p = 0.020) (Table 6 and Fig. 2).
Elevation of lactate levels was also significantly
more common in the acute MY subgroup than in the
acute ON subgroup (48.6% vs. 17.9%) (p < 0.007),
and CSF lactate concentrations were significantly
higher in the MY subgroup (p < 0.0003) (Fig. 1). Im-
portantly, CSF lactate concentrations were signifi-
cantly correlated with spinal cord lesion load in
patients with acute myelitis (r = 0.646, i < 0.00009)
(Fig. 4). We also found a significant positive correl-
ation of L-lactate with the CSF WCC (both in the
total cohort [r = 0.583, p < 0.0000001] and in
patients with pleocytosis [r = 0.529, p < 0.00004]),
with QAlb (r = 0.503, p < 0.0000001) and with CSF
total protein (r = 0.513, p < 0.0000001) (Fig. 6). CSF
L-lactate was elevated in only 7.8% (4/51) samples
without pleocytosis but in 42.9% (24/56) of samples
with pleocytosis, in 73.9% (17/23) of samples if CSF
WCC exceeded 50 cells/μl, and in 82.4% (14/17) if
CSF WCC exceeded 100 cells/μl. The difference was
even more pronounced in the 'acute MY' subgroup
(0% vs. 52.9%, 76.2%, and 86.7%, respectively). In pa-
tients with pleocytosis, the frequency of samples with
elevated CSF L-lactate did not differ between samples
with or without neutrophil granulocytes, neither in
the total cohort (41.9% [18/43] vs. 42.9% [24/56]) nor
in the 'acute MY' subgroup (52.2% [12/23] vs. 52.9%
[18/34]). This renders it at least unlikely that granulo-
cytes were the main source of L-lactate in patients
with elevated CSF L-lactate levels. Accordingly, no
Table 7 CSF findings at the time of the first LP and at the time of follow-up
Units First LP ever Follow-up LPs, first LP/event
Pleocytosis, all acute attacks Samples 44/79 (55.7%) 10/23 (43.5%)
Pleocytosis, acute MY Samples 26/31 (83.9%) 6/9 (66.7%)
Pleocytosis, acute ON Samples 12/39 (30.8%) 3/11 (27.3%)
Pleocytosis, acute BRAIN Samples 5/7 (71.4%) 1/3 (33.3%)
OCB, all acute attacks Samples 7/73 (9.6%) 2/23 (8.7%)
OCB, acute MY Samples 1/27 (3.7%) 2/10 (20%)#
OCB, acute ON Samples 3/38 (7.9%) 0/10 (0%)
OCB, acute BRAIN Samples 2/7 (28.6%) 0/3 (0%)
IgG-IF > 10%, all acute attacks Samples 4/63 (6.3%) 3/24 (12.5%)
IgG-IF > 10%, acute MY Samples 2/26 (7.7%) 0/9 (0%)
IgG-IF > 10%, acute ON Samples 2/31 (6.5%) 0/9 (0%)
IgG-IF > 10%, acute BRAIN Samples 0/5 (0%) 0/3 (0%)
QAlb > Qlim(Alb), all acute attacks Samples 35/65 (53.8%) 7/23 (30.4%)
QAlb > Qlim(Alb), acute MY Samples 16/26 (61.5%) 6/10 (60%)
QAlb > Qlim(Alb), acute ON Samples 14/33 (42.4%) 1/10 (10%)
QAlb > Qlim(Alb), acute BRAIN Samples 4/5 (80%) 0/3 (0%)
CSF TP elevated, all acute attacks Samples 33/70 (47.1%) 9/23 (39.1%)
CSF TP elevated, acute MY Samples 15/27 (55.6%) 6/10 (60%)
CSF TP elevated, acute ON Samples 14/37 (37.8%) 1/10 (10%)
CSF TP elevated, acute BRAIN Samples 4/5 (80%) 2/3 (66.7%)
CSF L-lactate elevated, all acute attacks Samples 14/52 (26.9%) 2/13 (15.4%)
CSF L-lactate elevated, acute MY Samples 9/21 (42.9%) 1/5 (20%)
CSF L-lactate elevated, acute ON Samples 5/28 (17.9%) 1/8 (12.5%)
CSF L-lactate elevated, acute BRAIN Samples 0/3 (0%) 0/0 (0%)
Time since attack onset, acute LPs Days 7 (0-34) 9.5 (0-28)
To control for the fact that the number of CSF samples obtained per event differed among patients in the subgroup with follow-up LPs, only the first LP obtained
during each attack was taken into account for this analysis
IgG-IF intrathecal IgG fraction; OCB oligoclonal bands; QAlb CSF/serum albumin quotient; TP total protein; WCC white cell count
#p = n.s.
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significant correlation was found between CSF L-lac-
tate levels and neutrophil cell numbers in the small
subgroup (N = 19) of samples with available data (as
well as in the 'acute MY' subgroup and the subgroup
of samples with pleocytosis).
First vs. follow-up LP
The frequency of OCB was slightly higher among the
follow-up samples (11/58 [19%] vs. 9/93 [9.7%]). How-
ever, the difference was not statistically significant. All
initial LP were obtained after 2002 (median 2015),
largely ruling out the possibility that differences in IEF
sensitivity between older and more recent tests played a
major role. Moreover, the difference in OCB frequency
was seen only in the acute MY subgroup, not in the
acute ON or acute BRAIN subgroup. Finally, the
frequency of IgG-IF elevation, as a quantitative marker
for intrathecal IgG synthesis, did not differ between
initial and follow-up samples. Given all these findings, it
seems most likely that the difference in OCB frequency
was by chance.
The frequency of pleocytosis, BCB dysfunction, CSF
TP elevation, and CSF L-lactate elevation during acute
attacks also did not differ significantly between the first
LP and follow-up LP (Table 7).
However, changes were noted in individual patients
over time. A total of 51 repeat tests for OCB were per-
formed in 33 patients. OCB turned negative in at least
one repeat sample in 1 patient over the course of the
disease (absent 1 week after the initial LP and following
steroid treatment) (Supplementary Table 2). In 2 pa-
tients, OCB were negative at first LP and turned positive
at repeat examination 271 and 66 days later, respectively.
QIgG was normal in most of the OCB-positive samples,
indicating low levels of IgG IS.
In 26 patients, OCB were initially negative and
remained negative at follow-up. In 5 of these patients,
OCB pattern changed from pattern 1 to pattern 4, or
vice versa, over time. In three patients, OCB were posi-
tive at all LP performed (2 × 3 LP, 1 × 2 LP).
Similarly, QIgG was positive only transiently in 3/4 pa-
tients with quantitative evidence for IgG IS and available
follow-up results. 24/28 (85.7%) patients who were tested
more than once had a normal IgG CSF ratio both at first
LP and at follow-up. An 'IgM to IgG IS switch' was only
observed in 1/21 patients in whom QIgG and QIgM were
both determined more than once (QIgG negative but
QIgM positive at first LP, QIgG and QIgM positive at re-
peat LP a few days later and following treatment with
dexamethasone and intravenous methylprednisolone).
Table 8 CSF findings and attack severity
Units Severe attacks Mild/moderate attacks p value
WCC, all Cells/μl 43.3 (0-410; 35) 7 (0-463;83) 0.0005
WCC, elevated Samples 28/35 (80%) 44/83 (53%) 0.007
WCC, if elevated Cells/μl 47 (6-410; 28) 24 (6-463;44) n.s.
Neutrophils, all LPs Samples 8/17 (47.1%) 18/40 (45%) n.s.
OCB, pattern 2 or 3 Samples 5/32 (15.6%) 7/78 (9%) n.s.
Link index Samples 5/30 (16.7%) 4/68 (5.9%) n.s.
QIgG, all Ratio 4.2 (0.9-23.6; 30) 3.2 (1.1-14.1; 69) 0.012
QIgG, elevated Samples 4/30 (13.3%) 5/69 (7.2%) n.s.
QIgG, if elevated Ratio 4.7 (2.3-6; 4) 4.5 (2.4-7; 5) n.s.
QAlb, all Ratio 7.9 (3.2-32.7; 30) 5.7 (3-26.3; 74) 0.009
QAlb, elevated Samples 20/30 (66.7%) 29/74 (39.2%) 0.017
QAlb, if elevated Ratio 10.8 (6.5-32.7; 20) 8.3 (5.5-26.3; 29) 0.014
CSF TP, all mg/dl 55.1 (20.5-176; 31) 41.4 (20.4-171.8; 77) 0.026
CSF TP, elevated Samples 18/31 (58.1%) 31/77 (40.3%) n.s.
CSF TP, if elevated mg/dl 79 (46.7-176; 18) 62 (45.3-171.8; 31) 0.021
CSF TP, > 100mg/dl Samples 6/30 (20%) 3/85 (3.5%) 0.009
CSF L-lactate, all mmol/l 2 (1.4-4.4; 22) 1.8 (1.1_4; 56) n.s.
CSF L-lactate, elevated Samples 9/22 (40.9%) 16/56 (28.6%) n.s.
CSF L-lactate, if elevated mmol/l 3.1 (2.3-4.4; 9) 2.6 (2.1-4; 16) 0.037
CSF L-lactate, > 3 mmol/l Samples 6/25 (24%) 4/60 (6.7%) n.s.
Ratios and concentrations are given as median (with ranges and sample numbers in brackets)
IgG-IF intrathecal IgG fraction; OCB oligoclonal bands; QAlb CSF/serum albumin quotient; TP total protein; WCC white cell count
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In MRZR-negative patients, repeat lumbar puncture
was reported to increase the sensitivity of MRZR for
MS due to “broadening” of the MRZ reaction over
time [39]. It is therefore of note that some of the
sample used for MRZ testing were obtained at first
LP (N = 40), whereas others were obtained at follow-
up LP (N = 22); however, all were negative, irrespect-
ive of disease duration at the time of MRZ testing
(median 117.5 days since onset of 1st attack; range
06885). Moreover, in 9 patients, MRZR was tested
more than once. All 14 retests (1-5 per patient; me-
dian 1.5) in these patients were negative as well; the
median latency between first and last MRZR testing
was 766.5 days (range 10-2157).
Attack severity
Most CSF parameters assessed were higher and/or more
frequently pathologically altered in patients classified as
having a severe attack at the time of LP by the treating
physician than in patients classified as having mild or
moderate disease at the time of LP (Table 8), including,
among others, median CSF WCC (43.3 vs. 7 cells/μl; p <
0.0005); proportion of samples with pleocytosis (80% vs.
53%; p < 0.007); QIgG values (p < 0.012); QIgG positivity
rate (13% vs. 7%; p = n.s.); OCB positivity rate (16% vs.
9%; p = n.s.); rate of Link index (i.e., IgG index) elevation
(17% vs. 6%; p = n.s.); QAlb positivity rate (67% vs. 39%;
p = 0.017); median QAlb (7.9 vs. 5.7; p = 0.009); median
QAlb, if elevated (10.8 vs. 8.3; p < 0.014); median CSF
TP levels (p = 0.026); and presence of CSF TP exceeding
100 mg/dl (20% vs. 4%; p < 0.009). CSF TP concentra-
tions > 100 mg/dl or CSF L-lactate concentrations > 3
mmol/l were seen in none of the samples obtained from
patients with a mild attack at the time of LP but were
present in 20% and 24%, respectively, of patients with a
severe attack. See Table 8 for details.
Table 9 CSF findings in samples from patients with monophasic disease and from patients with relapsing disease
1st LP/event Units Monophasic Relapsing
Pleocytosis, acute attacks Samples 17/27 (63%) 37/74 (50%)§
Pleocytosis, acute MY Samples 12/14 (85.7%) 20/26 (76.9%)
Pleocytosis, acute ON Samples 3/9 (33.3%) 12/40 (30%)
Pleocytosis, acute BRAIN Samples 2/4 (50%) 4/6 (66.7%)
OCB, acute attacks Samples 4/25 (16%) 5/70 (7.1%)§
OCB, acute MY Samples 1/12 (8.3%) 2/25 (8%)
OCB, acute ON Samples 1/9 (11.1%) 2/38 (5.3%)
OCB, acute BRAIN Samples 2/4 (50%) 0/6 (0%)
IgG-IF > 10%, acute attacks Samples 1/21 (4.8%) 3/62 (4.8%)§
IgG-IF > 10%, acute MY Samples 1/12 (8.3%) 1/23 (4.3%)
IgG-IF > 10%, acute ON Samples 0/6 (0%) 2/33 (6.1%)
IgG-IF > 10%, acute BRAIN Samples 0/3 (0%) 0/5 (0%)
QAlb > Qlim(Alb), acute attacks Samples 12/21 (57.1%) 30/66 (45.5%)
§
QAlb > Qlim(Alb), acute MY Samples 8/12 (66.7%) 14/24 (58.3%)
QAlb > Qlim(Alb), acute ON Samples 2/6 (33.3%) 13/36 (36.1%)
QAlb > Qlim(Alb), acute BRAIN Samples 2/3 (66.7%) 2/5 (40%)
CSF TP elevated, acute attacks Samples 15/24 (62.5%) 27/68 (39.7%)§
CSF TP elevated, acute MY Samples 9/12 (75%) 12/25 (48%)
CSF TP elevated, acute ON Samples 4/9 (44.4%) 11/37 (29.7%)
CSF TP elevated, acute BRAIN Samples 2/3 (66.7%) 4/5 (80%)
CSF L-lactate elevated, acute attacks Samples 7/18 (38.9%) 8/46 (17.4%)§
CSF L-lactate elevated, acute MY Samples 6/10 (60%) 4/16 (25%)
CSF L-lactate elevated, acute ON Samples 1/6 (16.7%) 4/29 (13.8%)
CSF L-lactate elevated, acute BRAIN Samples 0/2 (0%) 0/1 (0%)
Time since attack onset, acute LPs Days 5 (0-31) 9.5 (0-34)
To control for differences in the number of follow-up samples available per patient, only the first LP performed during each acute event was considered
IgG-IF intrathecal IgG fraction; OCB oligoclonal bands; QAlb CSF/serum albumin quotient; TP total protein
§p = n.s.
Jarius et al. Journal of Neuroinflammation          (2020) 17:261 Page 16 of 26
LETM vs. non-longitudinally extensive transverse myelitis
(NETM)
While a significant correlation of CSF L-lactate, QAlb,
QIgG, and WCC with the total lesion load was found, as
described above, no statistically significant differences re-
garding the frequency of CSF pleocytosis, CSF-restricted
OCB, IF-IgG elevation > 10%, BCB dysfunction, or CSF
TP elevation were noted when samples were stratified into
acute LETM and acute NETM based on the presence or
absence of at least one lesion extending over three or
more VS (Supplementary Table 3). CSF L-lactate levels
were slightly yet statistically significantly higher in LETM
samples (p < 0.05).
Bilateral vs. unilateral ON
CSF findings in acute bilateral ON and unilateral ON
did not differ significantly, although more samples from
patients with acute bilateral ON than samples from pa-
tients with acute unilateral ON exhibited an increased
CSF WCC, a positive QAlb, or CSF TP elevation (Sup-
plementary Table 4).
Disease course
No statistically significant differences between samples
from patients with a monophasic disease course at last
follow-up and patients with a relapsing disease course
were observed during acute attacks with regard to the
frequency of CSF-restricted OCB, CSF pleocytosis, IgG-
IF > 10%, QAlb elevation, CSF L-lactate elevation, and
CSF TP elevation (Table 9).
Treatment status
No statistically significant differences were found be-
tween samples from patients untreated at the time of LP
(N = 102) and samples from patients treated with ste-
roids, immunosuppressants, or immunomodulatory
drugs at the time of LP (N = 56). Steroids used included
methylprednisolone, prednisone, and dexamethasone (N
= 47); immunosuppressive or immunomodulatory treat-
ments used included azathioprine, rituximab, fingoli-
mod, intravenous immunoglobulins, dimethyl fumarate,
teriflunomide, cyclophosphamide and were either used
alone (N = 9) or in combination with steroids (N = 9).
Surprisingly, pleocytosis, CSF-restricted OCB, elevated
QIgG, BCB damage (as suggested by an elevated QAlb),
and an increase in CSF TP concentrations were all found
with equal or even higher frequency with samples from
treated patients. The most likely explanation for these
findings is that more patients with a severe disease
course (and thus more pronounced CSF alterations, as
shown above) received treatment than did patients with
mild attacks (and thus less pronounced CSF alterations).
In fact, 52% of all samples obtained during severe at-
tacks, but only 33% of samples obtained during mild at-
tacks, were samples obtained from treated patients.
Moreover, patients with acute spinal cord or brain dis-
ease—and thus greater lesion volume and, in conse-
quence, often more pronounced CSF alterations, as
shown above—were more likely to receive treatment
than patients with acute ON (ON samples accounted for
only 34.8% of the 'treated acute samples' but for 43.1%
of all 'acute samples'). Finally, patients with mild or
moderate ON, the subgroup with the least probability of
Table 10 Demographic and CSF findings in MOG-EM stratified according to OCB status
OCB+ patients (at least once positive) OCB– patients (never positive)
Sex (m:f) Patients 1:1.5 1:1.5
Origin (non-Caucasion:Caucasian) Patients 1:14 1:11
Median age at first OCB+ LP Years 34 38
Median disease duration at first OCB+ LP Months 0 (0-16) 0 (0-489)
OCB+ all samples OCB− all samples
Pleocytosis Samples 13/19 (68.4%) 57/128 (44.5%) p = n.s.
WCC Samples 14 (0-151) 4 (0-463) p = n.s.
WCC > 150 Samples 1/18 (5.6%) 9/128 (7%) p = n.s.
Granulocytes Samples 3/10 (30%) 26/62 (41.9%) p = n.s.
QAlb > Qlim(Alb) Samples 11/17 (64.7%) 51/117 (43.6%) p = n.s.
CSF TP elevated Samples 8/18 (44.4%) 50/122 (41%) p = n.s.
CSF L-lactate elevated Samples 3/12 (25%) 22/91 (24.2%) p = n.s.
Treated at the time of OCB testing Samples 10/20 (50%) 48/131 (36.6%) p = n.s.
Time since attack onset Days 14 12.5
IgG-IF intrathecal IgG fraction; OCB oligoclonal bands; QAlb CSF/serum albumin quotient; TP total protein; WCC white cell count
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pathological CSF alterations, were underrepresented in
the treated subgroup when compared with the total co-
hort, further strengthening the effect.
OCB-positive vs. OCB-negative MOG-EM
OCB-positive patients did not differ significantly from
OCB-negative patients with regard to age, sex, origin, or
disease duration. Similarly, no marked differences were
found between OCB-positive and OCB-negative samples
regarding most CSF parameters, with the exception of a
higher rate of pleocytosis (p = n.s.) and a slightly higher
median WCC in the OCB-positive subgroup (p = n.s.),
possibly indicating slightly more severe disease among
those patients (Table 10).
Acute attacks vs. remission
A significantly higher frequency of pleocytosis (94.7% vs.
13.5%; p < 0.005), a significantly higher CSF WCC (p <
0.0007) and a significantly higher frequency of CSF L-
lactate elevation (31.6% vs. 5%; p = 0.020) were found in
CSF samples obtained during acute attacks compared to
samples obtained during remission if all samples were
taken into account (see Tables 1, 2, 3, 4, 6 and Fig. 2).
When considering only the first LP performed during
acute events and the latest LP performed during remis-
sion of an event (in order to control for differences in
the number of follow-up samples available per patient),
some differences were more pronounced (Table 11 and
Fig. 2). However, highly statistically significant differ-
ences were found only for pleocytosis rate (p < 0.0004)
and CSF WCC numbers (p < 0.0002). A less marked dif-
ference was observed for QIgM (p < 0.03).
Finally, separate analyses of the 'acute MY', the 'acute
ON', and the 'acute BRAIN' subgroups revealed more
pronounced differences between the acute phase and
remission than is evident from the unstratified analysis
of the total cohort (see Supplementary Table 1, Table
11, and Fig. 2).
'Normal' CSF
A substantial number of CSF samples exhibited no patho-
logical changes. If CSF WCC, OCB, QIgG, Link index,
QIgM, QIgA, QAlb, CSF TP, and CSF L-lactate are taken
into account 15/163 (9.2%) samples showed exclusively
normal values. Of these 15 samples, 5 were taken during
remission and 10 during acute attacks. Most of the 'acute'
samples were obtained from patients with ON (N = 7). If
only a basic panel consisting of CSF WCC, CSF TP, and
CSF L-lactate is considered (reflecting clinical practice in
some non-tertiary centers and in emergency room set-
tings), 34/163 (21%) samples would have been classified as
Table 11 CSF findings during acute attacks (first LP/event) and during remission (last LP/event)
Units Attack, all, first LP/event Remission, all, last LP/event p values
Pleocytosis Samples 54/102 (52.9%) 2/20 (10%) p = 0.0004
WCC Cells/μl 6.5 (0-463; 100) 2 (0-16; 19) p < 0.0002
WCC > 100/μl Samples 13/101 (12.9%) 0/20 (0%) p = n.s.
OCB Samples 9/96 (9.4%) 2/20 (10%) p = n.s.
QIgG > Qlim(IgG) Samples 6/85 (7.1%) 1/18 (5.6%) p = n.s.
QIgG Ratio 3.47 (0.9-23.61; 84) 2.66 (1.47-6.7; 18) p = n.s.
IgG-IF > 10% Samples 4/84 (4.8%) 0/18 (0%) p = n.s.
QIgM > Qlim(IgM) Samples 11/73 (15.1%) 0/15 (0%) p = n.s.
QIgM Ratio 0.59 (0-13.81; 72) 0.3 (0-1.36; 15) p < 0.03
QIgA > Qlim(IgA) Samples 3/72 (4.2%) 1/15 (6.7%) p = n.s.
QIgA Ratio 1.76 (0-17.27; 71) 1.94 (0-4.83; 15) p = n.s.
QAlb > Qlim(Alb) Samples 42/88 (47.7%) 5/18 (27.8%) p = n.s.
QAlb Ratio 6.46 (2.98-32.67; 88) 5.55 (3.13-15.33; 18) p = n.s.
CSF TP elevated Samples 42/93 (45.2%) 5/20 (25%) p = n.s.
CSF TP concentration mg/dl 44.5 (20.5-176; 85) 36.65 (5.11-101; 18) p = n.s.
CSF TP > 100mg/dl Samples 7/93 (7.5%) 1/20 (5%) p = n.s.
CSF L-lactate elevated Samples 16/65 (24.6%) 0/15 (0%) p = 0.033
CSF L-lactate concentration mg/dl 1.82 (1.05-4.43; 62) 1.7 (1.33-2.1; 14) p = n.s.
CSF L-lactate > 3mmol/l Samples 4/65 (6.2%) 0/15 (0%) p = n.s.
Time since attack onset Days 8 (0-34; 104) 191 (117-2624; 20)
Ratios and concentrations are given as median (with ranges and sample numbers in brackets)
IgG-IF intrathecal IgG fraction; OCB oligoclonal bands; QAlb CSF/serum albumin quotient; TP total protein
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“normal.” Of those, 19 (56%) would have been false-
negatives (with the full panel serving as a gold standard).
Quotient diagrams (“reibergrams”)
Plots of QIgG, QIgA, and QIgM, respectively, against
QAlb as a measure of BCB function are shown in Fig. 7.
Discussion
In this study, which is the largest and most comprehen-
sive study on CSF findings in MOG-EM conducted to
date, we demonstrate that CSF findings in MOG-EM are
clearly different from those reported in MS [27, 40]. Our
findings add further evidence in favor of the hypothesis
that MOG-IgG-positive EM is a disease in its own right
rather than a subvariant of MS [41–44].
Most strikingly, 131/151 (87%) samples showed no signs
of intrathecal synthesis (IS) of IgG, as indicated by a lack
of CSF-restricted OCB. This is in stark contrast to MS, in
which OCB are detectable in ≥ 95% of cases [27, 40]. In
those samples positive for OCB, the amount of intra-
thecally produced IgG was mostly low, as indicated by
normal QIgG in 10/17 samples. In the few samples with
quantitative evidence of intrathecal IgG synthesis (i.e.,
with elevated QIgG), the intrathecal IgG fraction was
below the second decile in the IgG-specific reibergram in
7/10 (70%) cases and was even below 10% in 5/10 (50%).
Moreover, quantitative evidence of intrathecal total IgG
synthesis, if present at all, was found exclusively during
acute disease attacks and was present only transiently in
3/4 patients with available follow-up data. Similarly, OCB
were only transiently positive in 3/6 OCB-positive patients
tested more than once (Supplementary Table 2). This is in
contrast to the temporal invariance of intrathecal IgG syn-
thesis deemed typical for MS [45], again suggesting a dif-
ferential immunopathogenesis of the two disorders.
Temporal variance of the patient’s OCB status has also
been observed in patients with AQP4-IgG-positive
NMOSD [15, 46].
The specificity of the intrathecally produced IgG frac-
tion in the few OCB-positive patients with MOG-EM is
unknown. MOG-IgG have been previously reported to be
present in the CSF in a subset of patients with MOG-EM
[47–49]. However, MOG-IgG is primarily produced in the
Fig. 7 CSF/serum quotient diagrams for IgG, IgM, and IgA
(“reibergrams”). Individual CSF/serum ratios of IgG, IgA, and IgM are
plotted against CSF/serum albumin ratios. Values above the upper
hyperbolic discrimination line, Qlim, indicate intrathecal synthesis of
the respective immunoglobulin (Ig) class. Individual intrathecal
fractions, IgIF, can be directly read by interpolation from the
percentiles above Qlim (median values are given in Tables 2 and 3).
IgG/A/M, immunoglobulin G/A/M; QIgG/A/M, CSF/serum IgG/A/M
ratios; QAlb, CSF/serum albumin ratio
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periphery, i.e., extrathecally, as suggested by a negative
MOG-specific AI [2]. This is similar to AQP4-IgG-
positive NMOSD, in which the pathogenic antibody is also
predominantly produced extrathecally [46, 48–50]. While
the latter fact does not rule out the possibility that a small
proportion of MOG-IgG is produced intrathecally, it is
unlikely that intrathecally produced MOG-IgG contrib-
utes much to the intrathecally produced IgG fraction de-
tectable in some patients, since antigen-specific AI are
generally considered to be more sensitive than OCB and
QIgG (which measure total IgG). Alternatively, the intra-
thecally produced IgG could reflect secondary B cell acti-
vation, e.g., targeted at antigens unmasked by primary
inflammatory tissue damage. Finally, it might be related to
coexisting conditions in some patients. Connective tissue
disorders (CTD), for example, which relatively frequently
co-exist with AQP4-IgG-positive NMOSD [51–53], are
associated with OCB in neurological patients in about 25-
30% of cases [54, 55]. However, signs of CTD were docu-
mented in none of the OCB-positive MOG-EM patients
in the present study (except for ANA). OCB can be ob-
served also in CNS infection. Similar to NMOSD and MS,
attacks in MOG-EM have been indeed reported to be pre-
ceded by viral or bacterial infections (or vaccination) in up
to 30% of cases [56]. It is therefore of note that OCB pat-
terns 3 and 4, indicating possible systemic infection at the
time of LP, were present in 33/150 (22%) samples. More-
over, three OCB-positive patients showed a single positive
anti-viral AI (2 × VZV, 1 × EBV), one OCB-positive pa-
tient suffered from possible zoster thoracicus 2-3 weeks
before onset of disease and LP (interestingly, an episode of
possible herpes zoster preceded disease onset and LP also
in a second, though OCB-negative, patient in this cohort
by 2-3 weeks), and one had a history of borreliosis.
Importantly, the intrathecal, polyspecific antiviral IgG re-
sponse typically found in MS (also termed MRZ reaction)
was absent in all samples tested (N = 62). This is similar to
what has been reported in NMOSD [37, 38, 57]. By con-
trast, a positive MRZ reaction is detectable in around 60-
70% of patients with classic MS [36, 37]. The lack of MRZ
in patients with MOG-EM, one of the most important dif-
ferential diagnoses of MS, adds to previous evidence indi-
cating a very high specificity of the MRZ reaction for MS.
The MRZ reaction is currently considered the laboratory
marker with the highest positive likelihood ratio for MS
[36, 38, 57, 58]. Its absence in MOG-IgG-positive patients
strongly supports the notion that MS and MOG-EM are
two pathophysiologically distinct diseases (Fig. 5).
Finally, the possibility of false-positive results needs to
be taken into account. QIgG results should be inter-
preted with caution whenever IgG-IF values are below
10%, owing to the limited precision of IgG measure-
ments in serum and CSF, which are inherent to the
methods (nephelometry) used, if supporting evidence
from OCB determination (which, performed properly, is
substantially more sensitive than QIgG) is lacking.
Current guidelines on CSF diagnosis set the upper limit
for imprecision at 7-10%, for incorrectness at 10%, and
for deviation between single measures at 24-30% [30]. In
fact, IgG-IF was below 10% and OCB were negative or
were not tested in 3 samples from 3 patients. If QIgG re-
sults not supported by either an IF-IgG > 10% or CSF-
restricted OCBs are not considered true positive (as rec-
ommended by some authors [30]), QIgG elevation was
present only in 8/133 (6%) samples from 6 out of 88
(6.8%) patients tested for QIgG at least once (including
the two VZV-AI-positive patients), indicating that IS of
IgG to an extent that is detectable quantitatively is rare
in MOG-EM. If the two VZV-AI-positive patients are
excluded as well (since intrathecal VZV infection may
sufficiently explain QIgG elevation), only 4 patients
showed an elevated QIgG, in at least two of whom QIgG
was positive only transiently.
There is still no standardized assay for detecting
MOG-IgG. Given the rarity of MOG-EM, very high
assay specificity is required to avoid an unfavorable ratio
of false-positive to true-positive results. However, none
of the assays published so far has been evaluated in suffi-
ciently large control cohorts to meet that requirement.
As in our previous studies on MOG-IgG [2–5]—and dif-
ferent from most studies in the field—the present study
therefore included almost exclusively patients tested
positive for MOG-IgG in at least two methodologically
independent assays, resulting in high diagnostic accuracy
and diagnostic homogeneity of this cohort and thus im-
proved data quality/validity. We consider this one of the
strengths of the present analysis. For confirmation, sam-
ples were retested by means of up to four different as-
says performed in two different laboratories (Medical
University Innsbruck: H + L-specific live CBA, Fc-
specific live CBA; University of Heidelberg: Fc-specific
fixed CBA, IgG1-specific live CBA). Overall, 13 patients
from 5 centers proposed for inclusion were not included
in the study because re-testing did not confirm MOG-
IgG seropositivity. These samples were thus classified as
false positives. In all of these cases, a borderline or only
low-positive test result had been reported by the initially
testing laboratory. It is interesting in the present context
that 4 of the false positives had shown a positive MRZ
reaction, as typically seen in MS, one of whom had a
primary-progressive disease course, which is atypical in
MOG-EM but not infrequent in MS, and three of whom
had a relapsing-remitting disease course; all four met the
current diagnostic criteria for MS. Together with the
complete absence of a positive MRZ reaction among pa-
tients with confirmed MOG-IgG serostatus in our study,
this strongly suggests—in accordance with recent inter-
national recommendations on the diagnosis of MOG-
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EM [22, 59]—that a positive MRZ reaction should be
considered a diagnostic 'red flag', i.e., a finding that
should prompt physicians to critically challenge a “posi-
tive” MOG-IgG laboratory report.
Few (N = 13, or 12% based on Qlim, and N=6, or 5%,
based on IgM-IF > 10%) patients showed low intra-
thecal production of IgM antibodies. IgM IS was found
exclusively during acute attacks. Interestingly, in 9/107
(8.4%) cases, IS exclusively of IgM but not of IgG was
observed, whereas in the remaining four cases IgG and
IgM IS was present in parallel. By contrast, isolated
IgM IS is atypical in MS and should prompt doubt re-
garding that diagnosis. The specificity of the IgM anti-
bodies in our MOG-EM patients is unknown. Five of
the 13 CSF samples with elevated QIgM were available
for retrospective testing but were all negative for
MOG-IgG (testing performed after preabsorption of
total IgG to rule out false-positive or false-negative re-
sults [60]). To the best of our knowledge, there are also
no reports on marked IgM deposition in MOG-EM le-
sions (as seen in NMOSD) [61]. A previous study found
MOG-IgM in 2/23 MOG-IgG-positive serum samples
but did not test for MOG-IgM in the CSF [3]. Alterna-
tively, blood contamination could have played a role in
a subset of cases. QIgM is much more sensitive to
blood contamination than QIgG, and a relevant number
of erythrocytes were detectable in at least 2/13 QIgM-
positive patients. Finally, the intrathecal IgM fraction
was < 10% in 7/13 QIgM-positive patients. In patients
with such low IF values, false-positive QIgM results
(owing to unavoidable imprecision of IgM measure-
ments [30]) cannot be fully ruled out.
Blood CSF barrier disturbance as indicated by QAlb
elevation was common and more severe than in MS.
While QAlb is normal in around 90% of MS patients
[27, 33], it was elevated in almost every second MOG-
EM sample. This is very similar to the high frequency of
BCB disruption seen in AQP4-IgG-positive NMOSD
(51%) [46]. Similarly, QAlb values exceeding 12 × 10−3,
which are extremely rare in MS, were present in more
than a quarter of samples with elevated QAlb. This is of
importance, since extrathecally produced MOG-IgG
might gain access to the CNS via regions of disturbed
BCB permeability. It is of note that QAlb elevation was
observed also in a substantial number of samples ob-
tained during remission (median 213 days from last at-
tack), demonstrating long-lasting BCB damage in MOG-
EM (as previously seen also in AQP4-IgG-positive
NMOSD [46]). It is unclear whether this reflects slow re-
covery from severe damage or rather ongoing subclinical
inflammation, as suggested by the fact that MOG-IgG
(just like AQP4-IgG [62]), remains detectable, partly at
high levels, in many patients with MOG-EM also during
remission.
L-lactate CSF levels were elevated in more than a quar-
ter of our patients and, importantly, almost exclusively
during acute attacks, rendering CSF L-lactate a possible
marker of disease activity in MOG-EM (Table 6 and Fig.
2). This is similar to AQP4-IgG-positive NMOSD [46] but
in contrast to MS, in which L-lactate levels are usually
normal [63]. CSF L-lactate levels were particularly high in
patients with acute myelitis and were strongly correlated
with the cumulative spinal cord lesion load at the time of
acute myelitis (Figs. 1 and 4). Surprisingly, CSF L-lactate
levels also correlated significantly with QAlb. However, in
contrast to albumin and TP, median L-lactate levels are
physiologically higher in the CSF than in the serum. This
renders it unlikely that the observed increase in CSF L-lac-
tate levels was simply due to QAlb elevation and—in con-
sequence—that the correlation of CSF L-Lactate with
disease activity and lesion load was simply a result of in-
creased BCB permeability [64, 65]. It thus seems more
likely that CSF L-lactate and QAlb independently reflect
the extent of intrathecal inflammation. CSF L-lactate levels
were also strongly correlated with the CSF WCC.
Granulocytes are a known source of CSF L-lactate
[66–70]. However, the frequency of L-lactate elevation
did not differ between samples with and without granu-
locytes. Moreover, no significant correlation between
CSF granulocyte counts and CSF L-lactate levels could
be demonstrated in the present cohort. As a limitation,
the number of samples with exact data on CSF granulo-
cyte numbers was relatively small. L-lactate is thought to
be produced also by astrocytes following glutamate
stimulation [71, 72]. In NMOSD, in which we could also
demonstrate a correlation between CSF L-lactate levels
and the spinal cord lesion load, AQP4-IgG has been re-
ported to result in increased extracellular glutamate con-
centrations due to coupled endocytosis of AQP4 and the
excitatory amino acid transporter 2 (EAAT2) [73]. As
previously discussed [74], an increase in extracellular
glutamate could exert potentially detrimental effects also
by overstimulating glutamate receptors in neurons and
MOG-expressing oligodendrocytes [73]. It also renders
oligodendrocytes susceptible to immunoglobulin-
independent (alternative pathway) complement attack
[73, 75]. However, there is no evidence so far for marked
astrocytic dysfunction (e.g., resulting from inflammatory
bystander damage) in MOG-EM, and extracellular glu-
tamate concentrations have not been studied in MOG-
IgG-positive patients to the best of our knowledge. Fi-
nally, neurons may switch to glycolysis, in particular if
their capacity to metabolize anaerobically the lactate of
astrocytic origin is exhausted [72]. Further studies are
needed to better characterize the sources of intrathecal
L-lactate in MOG-EM.
An elevated WCC was found in about 60% of samples
from patients with active disease at the time of LP.
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Among CSF white cells, lymphocytes and monocytes
were predominant, followed by neutrophils, an immune
cell type never observed in MS (but in around 50% of
samples from patients with acute attacks of AQP4-IgG-
positive NMOSD [46]). In line with our demonstration
of a lack of intrathecal MOG-IgG production in MOG-
EM in a previous study [2], the lack of OCB and the
normal QIgG values in most patients, and the lack of a
positive MRZ reaction in our patients, antibody-
secreting plasma cells were present only in 3.9% of all
samples. The proportion of samples with activated lym-
phocytes (15.6%) was similar to that in AQP4-IgG-
positive NMOSD (20.5%) but much lower than that usu-
ally seen in MS (> 75%) [33].
While a CSF WCC > 50 cells/μl is rare in MS and
should prompt physicians to challenge the diagnosis,
white cell numbers > 50 were observed in 19% of all
samples, in 27% of all samples with pleocytosis, and in
as many as 46% of those taken during acute myelitis
(52% if lesions were longitudinally extensive). In the
acute MY subgroup, WCC exceed even 100 cells/μl in
every third patient; such high white cell numbers are vir-
tually never seen in MS.
Neutrophil granulocytes or elevated CSF lactate levels,
two laboratory features of bacterial CNS infection, were
frequently observed during acute attacks. Granulocytes
are also detectable in the CSF during very early-stage
viral encephalomyelitis. Given the fact that MOG-EM at-
tacks (in common with NMOSD attacks [15, 56]) are
often preceded by infections [3, 4] which may result in
fever or blood leukocytosis, this might well lead to the
false suspicion of infectious disease in some cases. How-
ever, in most samples, both CSF lactate levels and abso-
lute CSF white cell numbers were much lower in MOG-
EM than in typical bacterial meningitis. While lactate
concentrations exceeded the age-dependent reference
range in 26% of all cases, lactate concentrations > 3 or >
4 mmol/l, as seen in a majority of patients with acute
bacterial meningitis, were absent in 90% and 98% of
cases, respectively.
Eosinophilic infiltration is not a typical feature of
MOG-EM [76, 77]. In line with that observation, eosino-
phils were absent in all but 2 samples in the present co-
hort (1 × 1% of all white cells; 1 × number not
specified). This is similar to MS, in which eosinophils
are typically absent in the CSF, too. By contrast, previous
studies have demonstrated the presence of eosinophil at-
tractants in the CSF of patients with NMO [78], eosino-
philic infiltration in NMO lesions [61], and the presence
of eosinophils in 10-15% of acute CSF samples from pa-
tients with AQP4-IgG-positive NMOSD [46].
It is important to keep in mind that CSF pathology in
MOG-EM varies markedly depending on disease activity,
attack severity, and lesion location, and may be even
absent in some cases. Of note, CSF pathology was strik-
ingly less severe and less frequent in samples obtained
during acute attacks of ON than in acute myelitis (Fig.
1). Patients presenting with isolated brain lesions exhib-
ited CSF alterations more severe than in ON but less se-
vere than in myelitis. These findings are well in line with
the fact that the lesion volume is rather small in ON
compared with myelitis (median lesion load 5 VS; up to
21 VS; LETM in 64%). Moreover, lumbar CSF in general
does not reflect supratentorial lesions well due to its re-
moteness from the actual site of inflammation (so-called
caudal–rostral CSF gradient). Moreover, we found highly
significant differences in terms of CSF pathology (espe-
cially with regard to WCC, pleocytosis rate, QAlb, and
TP) between attacks classified as “severe” by the treating
physicians and attacks classified as only “mild” or “mod-
erate” in this study. Future studies should attempt to
define more objective measures for attack severity
classification.
With the re-integration of OCB in the latest revision
of the diagnostic criteria for MS [79] and the demon-
stration of substantial differences in CSF profiles be-
tween MS and its most important mimics [36, 38, 46,
57, 80–82], LP may be performed more often in the fu-
ture. Although LP is a relatively safe procedure and
routinely used in many countries, adverse event such as
headache (post-puncture CSF pressure syndrome, the
frequency of which can be substantially lowered by use
of so-called atraumatic 22-24 gauge needles with con-
ical tip and lateral opening [“Sprotte needles”]), radicu-
lar symptoms, non-specific back pain, disc prolapse, or
aseptic disc necrosis (extremely rare), bleeding or infec-
tion rarely occur and a number of absolute (increased
intracranial pressure with progressive herniation as in-
dicated clinically and/or by MRI or CT; inflammatory
infiltration of the skin in the puncture area) and relative
(platelet counts < 50 GPt/L; therapeutic heparinization;
oral anticoagulation) contraindications exist [33]. In
consequence, patients should be thoroughly examined
and contraindications carefully considered before per-
forming LP. For a more detailed review of LP tech-
niques and the prevention and management of
complications see [33, 34].
Strengths and limitations
We count among the particular strengths of this study
the high number of patients included (given the rarity of
the disease), the large number of both samples and pa-
rameters analyzed, the stratified analysis taking into ac-
count the clinical presentation at the time of LP, and, in
particular, the fact that, in contrast with most previous
studies on MOG-EM, samples were tested for MOG-
IgG by means of at least two methodologically independ-
ent assays in almost all cases.
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It is a potential limitation that our study was per-
formed retrospectively and included a large number of
university centers. However, the rarity of MOG-IgG-
positive EM means that prospective monocenter studies
cannot be performed if sufficient sample numbers are to
be analyzed. Moreover, the multicenter approach re-
duces the risk of selection bias. Second, MRI data were
obtained retrospectively. Although the correlation of lac-
tate and TP levels with the spinal cord lesion load found
in our cohort is intriguing, further studies are needed to
confirm this finding in a prospective fashion. Third, no
statistically significant differences were observed be-
tween treated and untreated patients in this cohort;
however, as a limitation, it must be kept in mind that
the number of samples obtained during immunosup-
pressive treatment at the time of LP was low. Accord-
ingly, a type-II error cannot be excluded. As a general
rule, LP should be performed before commencement of
immunosuppressive or immunomodulatory treatment in
patients with suspected inflammatory CNS disorders if
the procedure is considered diagnostically relevant and
not expected to delay treatment significantly.
Conclusion
In summary, our study, the first to review comprehen-
sively and systematically the CSF findings in MOG-EM
in a large cohort of patients of mainly Caucasian des-
cent, demonstrates that (i.) in sharp contrast to classic
MS, intrathecal IgG synthesis is rare in MOG-IgG-
positive EM, as shown both qualitatively and quantita-
tively; and (ii.), if present, intrathecal IgG synthesis is
low in most patients, often transient, and mainly re-
stricted to acute attacks (again in contrast to MS). More-
over, our data show that (iii.) CSF findings in acute
myelitis differ substantially and significantly from those
in acute ON (normal CSF findings are frequent in ON
and do not exclude the diagnosis), which is of high po-
tential clinical relevance; that (iv.) CSF findings in
“monophasic” MOG-EM are not significantly different
from those in relapsing MOG-EM; and that, different
from MS, (v.) the degree of CSF alteration depends sig-
nificantly on disease activity and attack severity (and
could thus have potential prognostic value) in MOG-
IgG-positive patients. Notably, (vi.) CSF L-lactate levels,
QAlb, and CSF TP levels correlated with the spinal cord
lesion load in patients with acute myelitis (again suggest-
ing a potential prognostic value of LP in MOG-EM).
Our finding that (vii.) CSF white cell numbers in MOG-
EM may well exceed those typically observed in MS, in
particular in acute myelitis (> 50 cells/μl in around 50%
during acute LETM); that (viii.) a lack of pleocytosis, on
the other hand, does not rule out the condition but is a
frequent finding (around 66% in acute ON), and that
(ix.) the intrathecal, polyclonal antiviral immune
response (so-called MRZ reaction) discriminates sharply
between MOG-EM and MS, and a positive MRZ reac-
tion in patients with suspected MOG-EM may indicate a
false-positive MOG-IgG result are all of differential diag-
nostic relevance. Moreover, (x.) neutrophilic pleocytosis
and elevated L-lactate CSF concentrations render the
condition—just like AQP4-IgG-positive NMOSD—a
relevant differential laboratory diagnosis of (especially
nonpurulent or chronic) bacterial infection in a subset
of patients. Finally, we show that (xi.) QAlb and WCC
are relatively frequently elevated also during remission,
indicating sustained blood CSF barrier dysfunction and
possibly subclinical inflammation in patients with MOG-
EM. In many respects, CSF findings in MOG-EM share
much more similarities with NMOSD than with MS.
Our data may help to improve the differential diagnosis
of MOG-EM and MS and to extend our understanding
of the immunopathology of this newly described entity.
A detailed analysis of the CSF findings in pediatric pa-
tients with MOG-EM can be found in part 2 of this art-
icle series [83].
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